Semifluorinated alkane technology brings advantages for topical therapy
Semifluorinated alkane technology has novel physicochemical properties that explain its benefits as an ocular lubricant and support its use for developing a well-tolerated, preservative-free, multidose preparation of cyclosporine.
Reviewed by Edward J. Holland, MD
Cincinnati, OH-Water-free vehicles based on semifluorinated alkane technology (EyeSol Platform Technology, Novaliq) have proven performance as an effective ocular lubricant and show promise for their ability to increase the solubility, stability, and bioavailability of topically delivered cyclosporine, said Edward J. Holland, MD.
The ocular lubricant contains perfluorohexyloctane (F6H8) and is already commercially available in Europe as an over-the-counter product (EvoTears).
Recent:
Currently, a phase II study is under way in the United States evaluating an investigational cyclosporine product (CyclASol, Novaliq) that formulates the immunomodulatory drug in the EyeSol Technology.
“Topical administration remains the mainstay for treatment delivery in ophthalmology, but local side effects can affect treatment adherence, and that is particularly true with cyclosporine,” said Dr. Holland, director of cornea services, Cincinnati Eye Institute, Cincinnati, OH. “The EyeSol vehicle allows for a preservative-free, multidose preparation of cyclosporine, and importantly, it may improve its tolerability.”
Related:
Formulations based on the EyeSol Technology are clear, have a refractive index that is similar to water, and do not cause blurring of vision.
Moreover, they do not require preservatives because they do not support microbial growth, and because they do not contain water, they eliminate the potential for hydrolytic reactions that cause drug degradation, said Michael O’Rourke, president, Scotia Vision Life Science Consultants, Tampa, FL.
Internal server error